As a leading innovation-driven corporation, Lilly is developing a growing portfolio of pharmaceutical products to meet some of the world's most urgent medical needs.

 Here is a listing of our current marketed portfolio of medicines. For full prescribing information, please click on the respective product website links.

• Alimta® (pemetrexed)
• Erbitux® (cetuximab)
• Gemzar® (gemcitabine hydrochloride)

• Effient® (prasugrel)
• Livalo® (pitavastatin)
• ReoPro® (abciximab)*

• Adcirca (tadalafil)

Diabetes

• Glucagon™ (glucagon for injection [rDNA origin])
• Humalog® (insulin lispro injection [rDNA origin])
• Humalog® Mix75/25™ (75% Insulin lispro protamine suspension, 25% insulin lispro injection [rDNA origin])
• Humalog® Mix50/50™ (50% Insulin lispro protamine suspension, 50% insulin lispro injection [rDNA origin])
• TRADJENTA™ (Linagliptin) tablets***

Diabetic Peripheral Neuropathic Pain (DPNP)

• Cymbalta® (duloxetine hydrochloride)

Men's Health

• Axiron® (testosterone)
• Cialis® (tadalafil)

Fibromyalgia

• Cymbalta® (duloxetine hydrochloride)

Growth Disorders

• Humatrope® (somatropin rDNA origin for injection, Lilly)

Neuroscience

• Cymbalta® (duloxetine hydrochloride)
• Strattera®(atomoxetine hydrochloride)
• Symbyax® (olanzapine and fluoxetine hydrochloride)
• Zyprexa® (olanzapine)

Osteoporosis

• Evista® (raloxifene hydrochloride)
• Forteo® (teriparatide of recombinant DNA origin)

 See our pipeline